Eyegate Pharmaceuticals (NASDAQ:EYEG) Upgraded to “Buy” at ValuEngine

ValuEngine upgraded shares of Eyegate Pharmaceuticals (NASDAQ:EYEG) from a hold rating to a buy rating in a research note released on Thursday, ValuEngine reports.

EYEG stock traded down $0.22 during midday trading on Thursday, reaching $6.68. 874 shares of the company’s stock traded hands, compared to its average volume of 939,523. The company has a market cap of $24.74 million, a price-to-earnings ratio of -1.48 and a beta of 2.55. The firm’s fifty day moving average price is $5.38 and its 200-day moving average price is $2.31. Eyegate Pharmaceuticals has a 52 week low of $2.25 and a 52 week high of $9.50.

In other news, major shareholder Armistice Capital Master Fund bought 605,001 shares of Eyegate Pharmaceuticals stock in a transaction dated Monday, September 30th. The stock was purchased at an average price of $3.12 per share, for a total transaction of $1,887,603.12. Corporate insiders own 47.50% of the company’s stock.

An institutional investor recently bought a new position in Eyegate Pharmaceuticals stock. Susquehanna International Group LLP bought a new position in Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 222,297 shares of the specialty pharmaceutical company’s stock, valued at approximately $53,000. Susquehanna International Group LLP owned approximately 0.49% of Eyegate Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 49.62% of the company’s stock.

Eyegate Pharmaceuticals Company Profile

EyeGate Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. Its proprietary platform technologies consist of crosslinked thiolated carboxymethyl hyaluronic acid (CMHA-S) and iontophoresis drug delivery system.

Further Reading: Market Timing

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.